XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies
September 20 2019 - 8:15AM
XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian
Patent Office has granted XBiotech a patent (Patent Number
56003542-6CA) covering the use of bermekimab in the treatment of
inflammatory skin diseases. The patent describes studies showing
that antibodies which specifically neutralize the activity of
interleukin-1alpha (IL-1α), such as bermekimab, reduce skin
inflammation and treat inflammatory skin diseases. XBiotech has
conducted a number of clinical trials in dermatology using
bermekimab, including studies in hidradenitis suppurativa, atopic
dermatitis, and psoriasis vulgaris (plaque psoriasis). The company
has also published clinical findings for the treatment of psoriasis
and acne. The development of bermekimab for the treatment of
inflammatory skin disorders is an important part of XBiotech’s
commercialization programs.
Stanley Kim, Ph.D., J.D., XBiotech’s Corporate
Vice President of Intellectual Property, stated, “I am pleased that
the Canadian Patent Office acknowledged the significance of
XBiotech’s contribution to this field by granting this patent with
broad claims. As a pioneer in IL-1α research, XBiotech has
developed a significant worldwide patent portfolio for the use of
anti-IL-1α antibody to prevent and treat inflammatory skin diseases
as well as other conditions involving sterile inflammation.”
This patent issuance in Canada further broadens
XBiotech’s patent portfolio as it relates to bermekimab and its
potential to treat inflammatory skin disorders through IL-1 alpha
blockade. The company has previously successfully completed
clinical studies evaluating bermekimab for treatment of atopic
dermatitis, psoriasis1, acne2, pyoderma gangrenosum, and
hidradenitis suppurativa3.
The grant of this patent in Canada is in
addition to patents granted in the U.S., Europe, Australia, and
Japan. The Company’s patent portfolio also includes several pending
U.S. and foreign applications directed to dermatologic
pathologies. XBiotech plans to continue to pursue inflammatory skin
disorder indications as it further strengthens its clinical
pipeline.
About 85 million Americans (approximately one in
four) sought treatment from a physician for skin disease in
2013—with an estimated direct health care cost of $75 billion, a
number which continues to grow. The economic impact and prevalence
of skin disease is on a similar magnitude as the other major
diseases affecting the U.S. population, including diabetes and
cardiovascular disease. Consequently, revenues from new biological
drugs to treat skin diseases are growing rapidly. XBiotech believes
bermekimab has the potential to emerge as a leading therapy for
skin disease.
About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company
dedicated to pioneering the discovery, development and
commercialization of therapeutic antibodies based on its True
Human™ proprietary technology. XBiotech currently is
advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and
infectious diseases. Headquartered in Austin,
Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information,
visit www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
ContactAshley
Oteroaotero@xbiotech.com512-386-2930
1 Coleman KM et al. Open-Label Trial
of MABp1, a True Human Monoclonal
Antibody Targeting Interleukin 1⍺, for the Treatment of
Psoriasis. JAMA Dermatol. 2015 May;151(5):555-6.
2 Carrasco D et al. An Open Label, Phase
2 Study of MABp1 Monotherapy for the Treatment
of Acne Vulgaris and Psychiatric Comorbidity. J Drugs
Dermatol. 2015 Jun;14(6):560-4.
3 Kanni T et al. MABp1 Targeting
Interleukin-1Alpha for Moderate to Severe Hidradenitis Suppurativa
not Eligible for Adalimumab: A Randomized Study. J Invest
Dermatol. 2017 Nov 9.
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Sep 2023 to Sep 2024